New hope for elderly lung cancer: One-Drug immunotherapy trial launches

NCT ID NCT07596121

Recruiting now Disease control Sponsor: Tang-Du Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the immunotherapy drug serplulimab alone can control advanced non-small cell lung cancer in patients aged 65 and older whose tumors have high PD-L1 levels. About 60 participants will receive the drug every three weeks until their disease worsens. The goal is to see how long the cancer stays under control and how safe the treatment is.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Serplulimab (an immunotherapy drug given by IV every 3 weeks)
What this could lead to: If it works, this could offer a simpler, single-drug treatment option for elderly lung cancer patients with high PD-L1 levels.
What could go wrong: This is an early, small Phase II trial with only 60 patients, so results may not apply widely. Immunotherapy can cause side effects like inflammation of the lungs or other organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CANCER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC (NON-SMALL CELL LUNG CANCER)

Contacts and locations

Locations

Tangdu Hospital Affiliated to the Fourth Military Medical University
RECRUITING

Xi'an, Shannxi, 710000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.